Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
July 16 2024 - 5:45AM
Business Wire
Symposia will highlight work to overcome
HIV-related stigma and discuss the evolving state of HIV treatment
and prevention
Merck (NYSE: MRK), known as MSD outside of the United States and
Canada, today announced upcoming data presentations and programming
at the 25th International AIDS Conference (AIDS 2024), taking place
July 22-26, 2024, in Munich, Germany. Merck will share updates on
new scientific findings from its HIV research program, including
Phase 1 results from a trial evaluating the potential for drug-drug
interaction between MK-8527, the company’s novel nucleoside reverse
transcriptase translocation inhibitor (NRTTI), and an oral
contraceptive. The company will also host a symposium exploring
HIV-related stigma and discrimination, as well as a symposium on
the importance of choice when considering HIV treatment and
prevention options.
“AIDS 2024 is such an important moment for the global HIV
community, and we are excited to be in Munich to showcase our
continued commitment to advancing research and supporting policy
initiatives to help address ongoing challenges and unmet needs,”
said Paul Schaper, associate vice president, Global Public Policy,
Merck. “We have been engaged in HIV research since the early days
of the epidemic and today we are proud to be working alongside
researchers, advocacy organizations, industry partners and others
to keep innovating for all those impacted by HIV”.
Merck will host two symposia during AIDS 2024 to discuss global
policies and issues impacting the HIV community:
- Coming Through that Fire: Transcending HIV-Related Shame and
Stigma, (July 23, 6-7:30pm CET): Community leaders from around the
world will discuss the impact of HIV-related stigma and
discrimination on efforts to reduce infections and reach global HIV
elimination goals. Learn more here.
- HIV Today and Tomorrow: The Evolving Importance of Choice (July
24, 12-1pm CET): Plenary presentations, case discussions, and
interactive panel discussions will highlight the unmet needs and
challenges facing current and future HIV treatment and prevention
efforts. Learn more here.
Abstracts in the AIDS 2024 program include:
- Phase 1, open-label study to evaluate the drug interaction
between MK-8527, an HIV-1 nucleoside reverse transcriptase
translocation inhibitor, and the oral contraceptive
levonorgestrel/ethinyl estradiol in healthy adult females, Poster
Session B6, Carstens, R, et al.
- Transmitted drug resistance to reverse transcriptase and
protease inhibitors in Argentina: an updated analysis, Poster
Session B11, Cecchini, D, et al.
- Long-Acting Oral PrEP is Preferred to Injections: Findings from
an Online Sample of American Gay, Bisexual, and Other Men who Have
Sex with Men, Poster Session E2, Gravett, R, et al.
- Lack Of Understanding of Undetectable Equals Untransmittable
(U=U) is High Among People Living With HIV in The United States,
Poster Session E2, Tadese, B, et al.
- Weight Gain and Health-Related Quality of Life in People with
HIV On Antiretroviral Therapy, Poster Session B4, Tadese, B, et
al.
For an overview of Merck’s HIV treatment and prevention clinical
development program, please click here.
Merck’s Commitment to HIV
For more than 35 years, Merck has been committed to scientific
research and discovery in HIV. Today, we are developing a series of
antiviral options designed to help people manage HIV and protect
people from HIV, with the goal of reducing infection worldwide. We
remain committed to collaborating with others in the global HIV
community to address the complex challenges that impede progress
toward ending the epidemic.
About Merck
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than
130 years, we have brought hope to humanity through the development
of important medicines and vaccines. We aspire to be the premier
research-intensive biopharmaceutical company in the world – and
today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive
global workforce and operate responsibly every day to enable a
safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect
with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline candidates that
the candidates will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716035213/en/
Media Contacts:
Deb Wambold (215) 779-2234 Julie Cunningham (617) 519-6264
Investor Contacts:
Peter Dannenbaum (732) 594-1579 Steven Graziano (732)
594-1583
Merck (NYSE:MRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Jul 2023 to Jul 2024